2. 浙江科技学院生物与化学工程学院, 杭州 310023
2. School of Biological and Chemical Engineering, Zhejiang University of Science and Technology, Hangzhou 310023, China
与大多数依赖配体和受体结合发挥作用的通路不同,Hippo通路是由核心激酶、效应因子、辅助因子和转录因子共同组成的激酶级联反应,调控细胞增殖分化、黏附和细胞代谢等生理过程。除跨膜蛋白、机械信号和细胞代谢产物等调控Hippo通路外,姜黄素、胆碱、白藜芦醇等营养素也能调控Hippo通路,提示Hippo通路可能是一些营养素发挥促畜禽生长发育作用的核心通路。因此,本文对Hippo通路的组成及作用模式、调控Hippo通路的各类因子和研究Hippo的试验方法进行综述,以期为利用Hippo通路进行营养干预提供理论依据和技术支持。
1 Hippo通路的组成和作用模式在哺乳动物体内,Hippo通路高度保守,如表 1所示,它由核心激酶、效应因子、辅助因子和转录因子共同组成。经典的Hippo通路核心激酶由哺乳动物STE-20样激酶1/2(mammalian STE20-like kinases 1/2,MST1/2)、Salvador同系物1(Salvador homolog 1,SAV1)、大肿瘤抑制因子1/2(large tumor suppressor kinase 1/2,LATS1/2)和MOB激酶激活因子1A/B(MOB kinase activator 1A/B,MOB1A/B)共同构成[1]。丝裂原活化蛋白激酶激酶激酶激酶(mitogen-activated protein kinase kinase kinase kinases,MAP4K)和核DBF2相关激酶1/2(nuclear DBF2-related 1/2,NDR1/2)是Hippo通路核心激酶的新增成员[2-3]。Yes相关蛋白(Yes-associated protein,YAP)和具有PDZ结合基序的转录共激活因子(transcriptional co-activator with PDZ-binding motif,TAZ)是Hippo通路的效应因子[1-3],14-3-3接头蛋白是调控YAP/TAZ核质定位的重要辅助因子[1-3]。转录增强缔合域蛋白(transcriptional enhanced associate domain,TEAD)是哺乳动物体内与YAP结合的主要转录因子[1-3]。
Hippo通路是一条激酶级联反应链。当Hippo通路被激活,MAP4K、MST1/2和SAV1共同磷酸化并激活下游的NDR1/2、LATS1/2和MOB1A/B[2-3]。活化的NDR1/2和LATS1/2进一步磷酸化YAP/TAZ[2-3],磷酸化的YAP/TAZ或者与14-3-3接头蛋白结合滞留胞质[1-3],或者在胞质中被泛素化降解[1-3]。反之,当Hippo通路失活,未磷酸化的YAP/TAZ进入细胞核,结合不同的转录因子,驱动下游基因转录,调控细胞的发育。
TEAD是YAP的主要转录伙伴[1-3]。YAP-TEAD转录模块可以激活富半胱氨酸61(cystein rich 61,CYR61)、含杆状病毒IAP重复蛋白5(baculoviral IAP repeat containing 5,BIRC5)、FOS样抗原1(FOS like antigen 1,FOSL1)、双调蛋白(amphiregulin,AREG)、肝素结合性表皮生长因子(heparin-binding EGF-like growth factor,HBEGF)和细胞周期蛋白D1(cyclin D1,CCND1)等调控细胞增殖分化、上皮间质转化、血管生成、细胞代谢、纤维发生和信号转导等[4-8]过程。NKX同源框-1(NK2 homeobox1,NKX2-1)、核小体改构复合体(nucleosome remodeling complex,NURD)、c-Jun氨基端激酶(c-Jun N-terminal kinase,JNK)和钙调蛋白结合转录激活因子1(calmodulin binding transcription activator 1,CAMTA1)是辅助TEAD转录的调节因子。YAP可结合TEAD/NKX2-1转录复合物调控肺的分化[9];结合TEAD/NURD维持细胞的生长和存活[10];结合TEAD/JNK调控细胞代谢[11];结合TEAD/CAMTA1促进血管生成[12]。YAP还可直接结合p73[13]、p63[14]、Myb-MuvB复合物(Myb-MuvB complex,MMB)[15]、配对盒因子3(paired box gene 3,PAX3)[16]、干扰素调节因子3(interferon regulatory factor 3,IRF3)[17]、Runt相关转录因子2(Runt-related transcription factor 2,RUNX2)[18]或T细胞因子/淋巴增强子结合因子(T-cell factor/lymphoid enhancer-binding factor,TCF/LEF)[19]调控细胞的增殖分化。YAP能结合短尾畸形(brachyury)蛋白调控细胞周期和维持细胞干性[20];结合Smad2/3蛋白[21]或T-box转录因子5(T-box transcription factor,TBX5)[22]调控纤维发生;结合磷酸化Jun氨基端激酶(phosphorylated Jun N-terminal kinases,pJNK)调控炎性因子表达[23];结合Krüppel样因子4(krüppel-like factor 4,KLF4)调控细胞黏附[24];结合叉头盒转录因子1(forkhead box O1,FOXO1)调控细胞死亡[25];结合p53转录因子调控细胞存活[26]。
2 调控YAP/TAZ转录的因子YAP/TAZ是Hippo通路的关键因子,必须入核才能驱动下游基因转录,使Hippo通路发挥作用。跨膜蛋白、机械信号和G蛋白偶联受体(G-protein-coupled receptors,GPCR)等通过调控Hippo通路核心激酶活性,影响YAP/TAZ转录;蛋白磷酸酶1(protein phosphatase 1,PP1)、Nemo样激酶(nemo-like kinases,NLK)和血影蛋白(spectrin)等可以直接调控YAP/TAZ转录。
2.1 依赖Hippo通路核心激酶调控YAP/TAZ转录的因子SCRIB极性蛋白(scribble,SCRIB)、TAO激酶(thousand and one kinases,TAOKs)和棕榈酸(palmitic acid,PA)等通过激活Hippo通路,诱导核心激酶磷酸化,抑制YAP/TAZ入核转录;纹状蛋白相互作用的磷酸酶和激酶复合物(striatin-interacting phosphatases and kinases,STRIPAK)、机械信号和代谢产物等通过抑制核心激酶活性,促进YAP/TAZ入核转录;Ras相关结构域家族蛋白(Ras association domain family,RASSFs)、受体酪氨酸激酶(receptor tyrosine kinase,RTK)和GPCR双向调控Hippo通路核心激酶,影响YAP/TAZ的核质定位。
2.1.1 激活Hippo通路的因子SCRIB可结合并激活MST1/2和LATS1/2[27]。肾脑蛋白(kidney and brain protein,KIBRA)、神经纤维蛋白2(neurofibromin 2,NF2)和FERM结构域蛋白6(FERM domain containing protein 6,FRMD6)组成复合物,与MST1/2和SAV1结合,促进LATS1/2磷酸化[28];Crumbs跨膜蛋白(CRBs)可结合KIBRA/NF2/FRMD6复合物,协同激活Hippo通路[29]。NF2也可直接诱导MST1/2和LATS1/2磷酸化,独立激活Hippo通路[30]。TAOKs可直接诱导MST1/2磷酸化,也可绕过MST1/2激酶,直接磷酸化LATS1/2[31]。非受体蛋白酪氨酸磷酸酶14(protein tyrosine phosphatase non-receptor type 14,PTPN14)可直接激活LATS1或与KIBRA互作协同激活LATS1[32]。PA可诱导MST1表达和磷酸化[33],激活Hippo通路。
2.1.2 抑制Hippo通路的因子STRIPAK超蛋白复合物、机械信号、葡萄糖(glucose,Glu)、氨基酸(amino acid,AA)、冠状动脉疾病相关连接蛋白(junctional protein-associated with coro-nary artery diseas,JCAD)、环状RNA PPP1R12A编码的小肽(circPPP1R12A-73aa)、B淋巴瘤Mo-MLV插入蛋白1(B lymphoma Mo-MLV insertion region 1,BMI1)、纤毛相关蛋白4(nephronophthisis 4,NPHP4)和盐诱导激酶2(salt-inducible kinase 2,SIK2)可抑制Hippo通路核心激酶的活性或表达。STRIPAK的成员纹状蛋白3(striatin 3,STRN3)、肌纤维膜结合蛋白(sarcolemmal membrane-associated protein,SLMAP)、蛋白磷酸酶2A(protein phosphatase 2A,PP2A)和丝氨酸/苏氨酸激酶25(serine/threonine kinase 25,STK25)协同抑制MST1/2的磷酸化[34];另一成员纹状蛋白4(striatin 4,STRN4)则会抑制MAP4K的磷酸化[35]。Ras同源基因家族成员A(Ras homolog gene family member A,RhoA)可感知细胞剪切力和胞外基质硬度等复杂的机械信号,重塑肌动蛋白(F-actin),抑制LATS1磷酸化[36]。代谢产物Glu和AA可抑制MST1/2激酶活性[37]。JCAD和BMI1能抑制LATS1/2磷酸化[38-39]。NPHP4可与LAST1共沉淀以下调LAST1表达[40],circPPP1R12A-73aa会下调MST1和LAST1的表达[41]。SAV1通过Ser168位点的磷酸化诱导YAP磷酸化,SIK2可磷酸化SAV1的Ser413位点,拮抗Ser168位点的磷酸化,抑制Hippo通路[42]。
2.1.3 双向调控Hippo通路的因子RASSFs、RTK和GPCR可双向调控Hippo通路。RASSF1A和RASSF5可激活MST1/2,而RASSF6会抑制MST1/2活性[43]。RTK和GPCR靶向LATS1/2激酶。大多数RTK会抑制LATS1/2活性,促进YAP/TAZ核内转录;但其相关配体或受体如酪氨酸激酶受体4(receptor tyrosine protein kinase 4,ERBB4)、Mer酪氨酸激酶(Mer tyrosine kinase,MerTK)、成纤维细胞生长因子2(fibroblast growth factor 2,FGFR2)和血管内皮细胞生长因子受体1(vascular endothelial growth factor receptor 1,VEGFR1)却能同时激活LATS1/2和促进YAP/TAZ核内转录[44]。与G12/13偶联受体(G12/13-coupled receptors,G12/13)或与Gq/11偶联受体(Gq/11-coupled receptors,Gq/11)结合的因子会抑制LATS1/2激酶活性,而与Gs偶联受体(Gs-coupled receptors,Gs)结合的因子会激活LATS1/2激酶活性[45]。
2.2 独立于Hippo通路核心激酶调控YAP/TAZ转录的因子PP1A、NLK和酰基甘油激酶(acylglycerol kinase,AGK)等可不依赖Hippo通路直接促进YAP/TAZ入核转录;血管动蛋白(angiomotin,AMOT)、E-钙黏蛋白(E-cadherin)、β-内酰胺酶(β-lactamase,LACTB)和色素框蛋白7(chromobox7,CBX7)等可不依赖Hippo通路直接抑制YAP/TAZ入核转录。
2.2.1 促进YAP/TAZ转录的因子YAP通过磷酸化的Ser127位点与14-3-3接头蛋白结合,滞留胞质。PP1A可使YAP的Ser127位点去磷酸化[46];NLK通过磷酸化YAP的Ser128位点,拮抗Ser127位点的磷酸化,解离YAP与14-3-3,促进YAP核易位[37]。AGK不仅能促进YAP核定位,还可与YAP形成正反馈回路,抑制LATS1/2表达[47]。骨形态发生蛋白2(bone morphogenetic protein 2,BMP2)会促进YAP核易位[48],骨形态发生蛋白6(bone morphogenetic protein 6,BMP6)可促进TAZ核定位[49]。Mastermind样蛋白1和2(Mastermind-like 1 and 2,MAML1/2)可同时促进YAP和TAZ的核定位,并形成稳定的MAML/YAP/TAZ核内复合物[50]。由髓锌指蛋白1(myeloid zinc finger 1,MZF1)和GA结合蛋白(GA binding protein,GABP)形成的转录因子复合物以及细胞周期蛋白依赖性激酶7(cyclin-dependent kinase 7,CDK7)都可促进YAP表达,并增强YAP核内表达的稳定性[51-52]。
2.2.2 抑制YAP/TAZ转录的因子AMOT、E-cadherin、闭锁小带蛋白-2(zonula occludens protein-2,ZO-2)和α-连环蛋白(α-catenin)通过把YAP阻滞在紧密连接或黏附连接处[53-54],抑制YAP入核;Spectrin通过调节皮质肌动球蛋白活性影响YAP的核质定位[55-56]。LACTB通过加强自身与PP1A结合来减弱PP1A对YAP的去磷酸化[46]。CBX7和应激诱导蛋白Sestrin2能抑制YAP核定位[57-58]。TEAD是YAP的主要转录因子,一些转录抑制因子,如退变样蛋白4(vestigial-like family member 4,VGLL4)[59]、前mRNA加工因子4激酶(pre-mRNA processing factor 4 kinase,PRP4K)[60]和CCAAT/增强子结合蛋白α基因(CCAAT/enhancer binding protein α gene,C/EBPα)[61]可竞争性结合TEAD,抑制YAP转录。
3 研究Hippo通路的方法构建条件性小鼠敲除模型和应用化学制剂是目前研究Hippo通路的2种常用试验方法。
3.1 Hippo通路的条件性小鼠敲除模型近交系小鼠C57BL/6是目前构建Hippo通路基因敲除模型的基础品系。基于C57BL/6小鼠,研究者已成功构建了全身性MST1[62]、MST2[62]、SAV1[63]、MOB1A[64]和MOB1B[64]单敲除模型以及MST1/2[62]和MOB1A/B[64]双敲除模型。
利用MST1和MST2全身性敲除小鼠与器官靶向性小鼠杂交,研究者成功构建了MST1/2+/-; Hnf1b-Cre[65]、MST1/2-/-; Hnf1b-Cre[65]、MST1/2-/-; HK[65]、MST1/2+/-; HK[65]、MST1-/-; MST2fl/fl; NKX2.1Cre/+[4]、MST1-/-; MST2fl/fl; NKX2.1Cre/Cre[4]和MST1-/-; MST2fl/fl; ShhCre/+[4]7种肺上皮特异性MST1/2双敲除模型;MST1fl/fl; MST2fl/fl; Osx-Cre[66]、MST1fl/fl; MST2fl/fl; hOC-Cre[66]和MST1fl/fl; MST2fl/fl; Col2a1-Cre[67]3种骨细胞相关模型;MST1fl/fl; MST2fl/fl; KSP-Cre[68]和MST1fl/fl; MST2fl/fl; YAPfl/fl; KSP-Cre[68]2种附睾上皮相关模型;MST1fl/fl; MST2fl/fl; Alb-Cre肝脏特异模型[8]以及MST1fl/fl; MST2fl/fl; Lyz-Cre巨噬细胞特异模型[69]。
利用SAV1全身性敲除小鼠与器官靶向性小鼠杂交,研究者成功构建了SAV1fl/fl; KSP-Cre[70]和SAV1fl/fl; Cdh16-Cre[71]2种肾脏特异性SAV1单缺失模型;FGFR4fl/fl; SAV1fl/fl; Alb-Cre[8]、Ptenfl/fl; SAV1fl/fl; Alb-Cre[72]和FGFR4fl/fl; SAV1fl/fl; YAPfl/+; Alb-Cre[8]3种靶向肝脏的复合敲除模型;SAV1fl/fl; Lin9fl/fl; NKX2.5-Cre[15]和SAV1fl/fl; Lin9fl/fl; αMhc-Cre[15]2种靶向心脏的复合敲除模型;Ptenfl/fl; SAV1fl/fl; Pdx1-Cre胰腺复合敲除模型[73];RASSF1a-/-; SAV1+/-[74]和RASSF1a-/-; SAV1+/+[74]2种全身性复合敲除模型。
通过敲除靶向器官的LATA1/2,研究者构建了LATS1fl/fl; LATS2fl/fl; NKX3.2-Cre[75]、LATS1fl/fl; LATS2fl/fl; Villin-Cre[76]、LATS1/2iΔPβC[77]和LATS1fl/fl; LATS2fl/fl; Lgr5-Cre[78]4种肠道相关模型;LATS1fl/fl; LATS2fl/+; Plp1-Cre[79]、LATS1fl/fl; LATS2fl/fl; Dhh-Cre[79]和LATS1fl/+; LATS2fl/fl; Hoxb7-Cre[80]3种雪旺细胞特异模型;LATS1del/fl; LATS2del/fl; Shh-Cre[81]肺泡上皮特异模型;LATS1fl/fl; LATS2fl/fl; Sox9-Cre[82]胆管上皮特异模型;LATS1fl/fl; LATS2fl/fl; TCF21i-Cre[83]心脏成纤维细胞特异模型和LATS1fl/fl; LATS2fl/fl; Sox9-Cre[82]导管细胞特异模型。
利用MOB1A、MOB1B全身性敲除小鼠与器官靶向性小鼠杂交,研究者构建了MOB1Afl/fl; MOB1Bfl/fl; Villin-Cre[84]、MOB1Afl/fl; MOB1B-/-; Rosa26-Cre[85]、MOB1Afl/flMOB1B-/-; Spc-Cre[86]和MOB1Afl/fl; MOB1Btr/tr; Krt14-Cre[64]4种上皮相关缺失模型;MOB1Afl/+; MOB1B-/-; Alb-Cre[6]肝脏特异缺失模型和MOB1Afl/fl; MOB1B-/-; Col2a1-Cre[87]软骨细胞特异模型。
通过条件性敲除,研究者构建了YAPfl/fl; NKX2.5-Cre[88]、YAPfl/fl; αMhc-Cre[89]和YAP+/fl; αMhc-Cre[90]3种心脏特异性YAP单敲除模型;YAPfl/fl; Spc-Cre[91]、YAPfl/fl; Krt14-Cre[5]和YAPfl/fl; Tek-Cre[92]3种上皮相关单缺失模型;YAPfl/fl; Alb-Cre[93]和Atg7fl/fl; YAPfl/fl; Alb-Cre[94]2种肝脏YAP缺失模型;YAPfl/fl; Has-Cre[95]肌肉细胞单缺失模型;YAPfl/fl; Nestin-Cre[96]和YAPfl/fl; Gfap-Cre[96]2种星形胶质细胞YAP缺失模型。研究者还构建了TAZfl/+; αMhc-Cre[89]、TAZfl/fl; Spc-Cre[91]和TAZfl/+; Cag-Cr[89]3种TAZ单敲除模型。在构建YAP/TAZ双敲除模型方面,研究者已成功构建了YAPfl/+; AZfl/fl; αMhc-Cre[89]、YAPfl/fl; AZfl/+; αMhc-Cre[89]和YAPfl/fl; AZfl/fl; αMhc-Cre[89]3种心脏特异性YAP/TAZ双敲除模型;YAPfl/fl; TAZfl/fl; NKX3.2-Cre[75]和YAP/TAZiΔPβC[77]2种肠道特异性YAP/TAZ双敲除模型;YAPfl/fl; TAZfl/fl; Shh-Cre[75]和YAPfl/fl; TAZfl/fl; Spc-Cre[97]2种肺上皮特异性双敲除模型;YAPfl/fl; TAZfl/fl; Col1a2-Cre[98]软骨双敲除模型;YAPfl/fl; TAZfl/fl; Col1a2-Cre[99]成纤维细胞双敲除模型;YAPfl/fl; TAZfl/fl; LysM-Cre[100]骨髓细胞双敲除模型;YAPfl/fl; TAZfl/fl; Emx1-Cre[101]神经胶质细胞双敲除模型;YAPfl/fl; TAZfl/fl; Cdh5-Cre[7]内皮细胞双敲除模型以及Ptenfl/fl; Sav1fl/fl; YAPfl/fl; TAZfl/fl; Alb-Cre[72]肝脏复合敲除模型。
3.2 调控Hippo通路的化学制剂Hippo通路由于会影响肿瘤细胞的迁移和侵袭,在肿瘤治疗中发挥重要作用。研究者研发出许多靶向Hippo通路的化学制剂,这些化学制剂主要作用于MST1/2-LATS1/2或YAP-TEAD 2个模块。
3.2.1 靶向MST1/2-LATS1/2的化学制剂XMU-MP-1、二甲双胍(metformin)、西格列汀(Sitagliptin)、C19小分子化合物、SHAP激活肽、F10叔酰胺衍生物、中草药吴茱萸碱(evodiamine)和葫芦素B(cucurbitacin B)、CL-6姜黄素衍生物、恶二唑衍生物(oxadiazole derivative)、麦冬素B(OP-B)、高三尖杉酯碱(HHT)、雷公藤苷(triptonide)、中国蜂胶(Chinese propolis)和酸枣仁活性成分JUA通过影响MST1/2-LATS1/2级联模块进而调控YAP/TAZ转录。XMU-MP-1是公认的MST1/2抑制剂,可直接抑制MST1/2和MOB1的磷酸化[102]。C19[103]、SHAP[104]、F10[105]、西格列汀[106]、吴茱萸碱[107]和CL-6[108]可增强MST1/2或LATS1/2的磷酸化水平。恶二唑衍生物[109]、麦冬素B[110]、葫芦素B[111]、二甲双胍[112]、高三尖杉酯碱[113]、雷公藤苷[114]、中国蜂胶[115]和JUA[116]通过调控MST1/2和LATS1/2的表达或定位,诱导YAP磷酸化。
3.2.2 靶向YAP-TEAD的化学制剂抗炎药物地塞米松(dexamethasone)是促进YAP转录的化学制剂。维替泊芬(verteporfin)、辛伐他汀(simvastatin)、青蒿素(artemisinin)、雌激素受体巴多昔芬(bazedoxifene)、中草药提取物RA-V和二柱解毒汤(EJD)、褪黑素(melatonin)、小分子MTX和CA3是抑制YAP转录的化学制剂。地塞米松可上调YAP总蛋白和YAP核蛋白的表达[117]。维替泊芬可上调接头蛋白14-3-3表达,促进14-3-3与YAP结合,诱导YAP胞质滞留[118]。青蒿素[119]、巴多昔芬[120]、RA-V[121]、辛伐他汀[122]和MTX[123]可增强YAP的磷酸化水平;二柱解毒汤[124]和CA3[125]可降低YAP和TAZ表达;褪黑素既可下调YAP/TAZ表达,又可诱导YAP磷酸化[126]。
TEAD是YAP的主要转录伙伴,Super-TDU模拟肽、Fisetin黄酮类化合物、LM98氟芬那酸类似物、MGH-CP1、NSC682769和CPD3.1是抑制YAP与TEAD结合的化学制剂。多肽Super-TDU竞争性结合TEAD[59],NSC682769竞争性结合YAP[127]以阻断YAP与TEAD结合。转录因子TEAD拥有一个保守的疏水口袋,是YAP与其结合的关键位点。Fisetin[128]、LM98[129]和MGH-CP1[19]均通过占据疏水的TEAD口袋,破坏YAP与TEAD结合。CPD3.1则可以直接抑制TEAD活性[130]。
4 营养素调控Hippo信号通路的作用机制通过营养干预促进动物生长发育一直是畜牧业研究的重点,而Hippo通路可能是一些营养素发挥作用的潜在机制。熊果酸(ursolic acid,UA)、岩藻多糖(fucoidan,FUC)和姜黄素(curcumin,CUR)都能够激活Hippo通路。UA通过激活RASSF1,上调MST1/2、LATS1和MOB1的表达,促进YAP磷酸化,下调靶基因CTGF的表达,抑制胃癌细胞存活[131]。FUC通过增强MST1/2、LATS1/2和YAP的磷酸化水平,诱导β-catenin胞质降解,阻断下游的β-catenin通路,进而抑制肿瘤细胞生长[132]。CUR通过促进TAZ磷酸化,驱动TAZ由胞核易位到胞质,抑制下游干性标志物基因CD133、EPCAM和OCT4的表达,减弱肺癌细胞干性[133];CUR还可通过抑制YAP/TAZ表达,降解KLF5蛋白,下调CCND1的表达,抑制膀胱癌细胞增殖[134]。叶酸(folic acid,FA)通过抑制LATS和YAP的磷酸化,下调Hippo通路,降低TEAD1和NLRP3炎性因子表达,缓解高葡萄糖对视网膜血管内皮细胞和心肌细胞的损伤[135-136]。胆碱(choline,CHO)供应不足会下调NF2表达,使视网膜细胞缓慢增殖、异常分化,但不会改变YAP/TAZ总蛋白的水平[137]。白藜芦醇(resveratrol,RES)具有双重调控Hippo信号通路的功能:既可通过降低炎性细胞因子表达,抑制Hippo激酶,促进YAP/TAZ入核,上调RUNX2的表达,促进成骨细胞分化[138];又可通过抑制RhoA活性,激活LATS1[139-140],诱导YAP磷酸化和胞质滞留[141],调控下游BAX/BCL-2的表达,诱导肝星状细胞凋亡[142]。目前营养素调控Hippo信号通路的研究主要集中在肿瘤细胞和受损伤细胞,Hippo信号通路对正常细胞的调控作用有待进一步探究。
5 小结Hippo通路作用广泛且调控网络复杂,它不仅对同一组织在不同状态下的调控存在差异,还与WNT、磷脂酰肌醇-3-羟激酶(PI3K)和哺乳动物雷帕霉素靶蛋白(mTOR)等通路存在复杂的互作效应。Hippo通路在动物营养领域的研究刚刚起步,揭示Hippo通路参与动物生长发育调控的路径和窗口期是利用Hippo通路促进动物生长发育的基础。筛选除熊果酸、姜黄素、白藜芦醇等以外的Hippo通路调控物质是利用Hippo通路促进动物生长发育的路径。WNT、PI3K和mTOR通路已被证实能够调节动物的生长、免疫以及氧化应激等过程,解析动物发育过程中WNT、PI3K和mTOR通路与Hippo通路的互作效应将是未来研究的一个方向,该研究将全面解析动物生长发育的调控网络,推动畜牧业发展。
[1] |
HONG W J, GUAN K L. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway[J]. Seminars in Cell & Developmental Biology, 2012, 23(7): 785-793. |
[2] |
MENG Z P, MOROISHI T, MOTTIER-PAVIE V, et al. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway[J]. Nature Communications, 2015, 6(1): 8357. DOI:10.1038/ncomms9357 |
[3] |
ZHANG L, TANG F Y, TERRACCIANO L, et al. NDR functions as a physiological YAP1 kinase in the intestinal epithelium[J]. Current Biology, 2015, 25(3): 296-305. DOI:10.1016/j.cub.2014.11.054 |
[4] |
LIN C W, YAO E, CHUANG P T. A conserved MST1/2-YAP axis mediates Hippo signaling during lung growth[J]. Developmental Biology, 2015, 403(1): 101-113. DOI:10.1016/j.ydbio.2015.04.014 |
[5] |
LIU M, ZHAO S Y, LIN Q J, et al. YAP regulates the expression of Hoxa1 and Hoxc13 in mouse and human oral and skin epithelial tissues[J]. Molecular and Cellular Biology, 2015, 35(8): 1449-1461. DOI:10.1128/MCB.00765-14 |
[6] |
NISHIO M, SUGIMACHI K, GOTO H, et al. Dysregulated YAP1/TAZ and TGF-β signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice[J]. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113(1): E71-E80. |
[7] |
WANG X H, FREIRE VALLS A, SCHERMANN G, et al. YAP/TAZ orchestrate VEGF signaling during developmental angiogenesis[J]. Developmental Cell, 2017, 42(5): 462-478.e7. DOI:10.1016/j.devcel.2017.08.002 |
[8] |
JI S Y, LIU Q X, ZHANG S H, et al. FGF15 activates Hippo signaling to suppress bile acid metabolism and liver tumorigenesis[J]. Developmental Cell, 2019, 48(4): 460-474.e9. DOI:10.1016/j.devcel.2018.12.021 |
[9] |
LITTLE D R, LYNCH A M, YAN Y, et al. Differential chromatin binding of the lung lineage transcription factor NKX2-1 resolves opposing murine alveolar cell fates in vivo[J]. Nature Communications, 2021, 12(1): 2509. DOI:10.1038/s41467-021-22817-6 |
[10] |
KIM N G, GUMBINER B M. Adhesion to fibronectin regulates Hippo signaling via the FAK-Src-PI3K pathway[J]. The Journal of Cell Biology, 2015, 210(3): 503-515. DOI:10.1083/jcb.201501025 |
[11] |
XU X M, NIE J, LU L, et al. YAP-TEAD up-regulates IRS2 expression to induce and deteriorate oesophageal cancer[J]. Journal of Cellular and Molecular Medicine, 2021, 25(5): 2584-2595. DOI:10.1111/jcmm.16266 |
[12] |
DRISKILL J H, ZHENG Y G, WU B K, et al. WWTR1(TAZ)-CAMTA1 reprograms endothelial cells to drive epithelioid hemangioendothelioma[J]. Genes & Development, 2021, 35(7/8): 495-511. |
[13] |
XIAO Q Q, QIAN Z L, ZHANG W Q, et al. Depletion of CABYR-a/b sensitizes lung cancer cells to TRAIL-induced apoptosis through YAP/p73-mediated DR5 upregulation[J]. Oncotarget, 2016, 7(8): 9513-9524. DOI:10.18632/oncotarget.7069 |
[14] |
ZHAO R, FALLON T R, SALADI S V, et al. Yap tunes airway epithelial size and architecture by regulating the identity, maintenance, and self-renewal of stem cells[J]. Developmental Cell, 2014, 30(2): 151-165. DOI:10.1016/j.devcel.2014.06.004 |
[15] |
GRVNDL M, WALZ S, HAUF L, et al. Interaction of YAP with the Myb-MuvB (MMB) complex defines a transcriptional program to promote the proliferation of cardiomyocytes[J]. PLoS Genetics, 2020, 16(5): e1008818. DOI:10.1371/journal.pgen.1008818 |
[16] |
MISKOLCZI Z, SMITH M P, ROWLING E J, et al. Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing[J]. Oncogene, 2018, 37(23): 3166-3182. DOI:10.1038/s41388-018-0209-0 |
[17] |
ZHANG T Q, ZHANG K P, JI K Y, et al. MicroRNA-365 inhibits YAP through TLR4-mediated IRF3 phosphorylation and thereby alleviates gastric precancerous lesions[J]. Cancer Cell International, 2020, 20(1): 549. DOI:10.1186/s12935-020-01578-0 |
[18] |
YING J, WANG P E, ZHANG S X, et al. Transforming growth factor-beta1 promotes articular cartilage repair through canonical Smad and Hippo pathways in bone mesenchymal stem cells[J]. Life Sciences, 2018, 192: 84-90. DOI:10.1016/j.lfs.2017.11.028 |
[19] |
LI Q, SUN Y, JARUGUMILLI G K, et al. Lats1/2 sustain intestinal stem cells and Wnt activation through TEAD-dependent and independent transcription[J]. Cell Stem Cell, 2020, 26(5): 675-692.e8. DOI:10.1016/j.stem.2020.03.002 |
[20] |
SHAH S R, DAVID J M, TIPPENS N D, et al. Brachyury-YAP regulatory axis drives stemness and growth in cancer[J]. Cell Reports, 2017, 21(2): 495-507. DOI:10.1016/j.celrep.2017.09.057 |
[21] |
SZETO S G, NARIMATSU M, LU M L, et al. YAP/TAZ are mechanoregulators of TGF-β-Smad signaling and renal fibrogenesis[J]. Journal of the American Society of Nephrology, 2016, 27(10): 3117-3128. DOI:10.1681/ASN.2015050499 |
[22] |
KOINIS F, CORN P, PARIKH N, et al. Resistance to MET/VEGFR2 inhibition by cabozantinib is mediated by YAP/TBX5-dependent induction of FGFR1 in castration-resistant prostate cancer[J]. Cancers, 2020, 12(1): 244. DOI:10.3390/cancers12010244 |
[23] |
WEI W, XUE L L, TAN L Y, et al. Inhibition of yes-associated protein dephosphorylation prevents aggravated periodontitis with occlusal trauma[J]. Journal of Periodontology, 2021, 92(7): 1036-1048. DOI:10.1002/JPER.19-0338 |
[24] |
MCGINN J, HALLOU A, HAN S, et al. A biomechanical switch regulates the transition towards homeostasis in oesophageal epithelium[J]. Nature Cell Biology, 2021, 23(5): 511-525. DOI:10.1038/s41556-021-00679-w |
[25] |
SHAO D, ZHAI P Y, DEL RE D P, et al. A functional interaction between Hippo-YAP signalling and FoxO1 mediates the oxidative stress response[J]. Nature Communications, 2014, 5: 3315. DOI:10.1038/ncomms4315 |
[26] |
YUAN F, WANG J L, LI R X, et al. A new regulatory mechanism between P53 and YAP crosstalk by SIRT1 mediated deacetylation to regulate cell cycle and apoptosis in A549 cell lines[J]. Cancer Management and Research, 2019, 11: 8619-8633. DOI:10.2147/CMAR.S214826 |
[27] |
MOHSENI M, SUN J L, LAU A, et al. A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway[J]. Nature Cell Biology, 2014, 16(1): 108-117. DOI:10.1038/ncb2884 |
[28] |
YU J Z, ZHENG Y G, DONG J X, et al. Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded[J]. Developmental Cell, 2010, 18(2): 288-299. DOI:10.1016/j.devcel.2009.12.012 |
[29] |
LING C, ZHENG Y G, YIN F, et al. The apical transmembrane protein Crumbs functions as a tumor suppressor that regulates Hippo signaling by binding to expanded[J]. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107(23): 10532-10537. DOI:10.1073/pnas.1004279107 |
[30] |
MATSUDA T, ZHAI P Y, SCIARRETTA S, et al. NF2 activates Hippo signaling and promotes ischemia/reperfusion injury in the heart[J]. Circulation Research, 2016, 119(5): 596-606. DOI:10.1161/CIRCRESAHA.116.308586 |
[31] |
FANG C Y, LAI T C, HSIAO M, et al. The diverse roles of TAO kinases in health and diseases[J]. International Journal of Molecular Sciences, 2020, 21(20): 7463. DOI:10.3390/ijms21207463 |
[32] |
WILSON K E, LI Y W, YANG N, et al. PTPN14 forms a complex with Kibra and LATS1 proteins and negatively regulates the YAP oncogenic function[J]. The Journal of Biological Chemistry, 2014, 289(34): 23693-23700. DOI:10.1074/jbc.M113.534701 |
[33] |
YUAN L S, MAO Y, LUO W, et al. Palmitic acid dysregulates the Hippo-YAP pathway and inhibits angiogenesis by inducing mitochondrial damage and activating the cytosolic DNA sensor cGAS-STING-IRF3 signaling mechanism[J]. The Journal of Biological Chemistry, 2017, 292(36): 15002-15015. DOI:10.1074/jbc.M117.804005 |
[34] |
BAE S J, NI L S, LUO X L. STK25 suppresses Hippo signaling by regulating SAV1-STRIPAK antagonism[J]. eLife, 2020, 9: e54863. DOI:10.7554/eLife.54863 |
[35] |
SEO G, HAN H, VARGAS R E, et al. MAP4K interactome reveals STRN4 as a key STRIPAK complex component in Hippo pathway regulation[J]. Cell Reports, 2020, 32(1): 107860. DOI:10.1016/j.celrep.2020.107860 |
[36] |
ZHANG Y L, LI Q, YANG X M, et al. SPON2 promotes M1-like macrophage recruitment and inhibits hepatocellular carcinoma metastasis by distinct integrin-Rho GTPase-Hippo pathways[J]. Cancer Research, 2018, 78(9): 2305-2317. DOI:10.1158/0008-5472.CAN-17-2867 |
[37] |
IBAR C, IRVINE K D. Integration of Hippo-YAP signaling with metabolism[J]. Developmental Cell, 2020, 54(2): 256-267. DOI:10.1016/j.devcel.2020.06.025 |
[38] |
YE J, LI T S, XU G, et al. JCAD promotes progression of nonalcoholic steatohepatitis to liver cancer by inhibiting LATS2 kinase activity[J]. Cancer Research, 2017, 77(19): 5287-5300. DOI:10.1158/0008-5472.CAN-17-0229 |
[39] |
SHIELDS C E, POTLAPALLI S, CUYA-SMITH S M, et al. Epigenetic regulator BMI1 promotes alveolar rhabdomyosarcoma proliferation and constitutes a novel therapeutic target[J]. Molecular Oncology, 2021, 15(8): 2156-2171. DOI:10.1002/1878-0261.12914 |
[40] |
HABBIG S, BARTRAM M P, MVLLER R U, et al. NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway[J]. The Journal of Cell Biology, 2011, 193(4): 633-642. DOI:10.1083/jcb.201009069 |
[41] |
ZHENG X, CHEN L J, ZHOU Y, et al. A novel protein encoded by a circular RNA circPPP1R12A promotes tumor pathogenesis and metastasis of colon cancer via Hippo-YAP signaling[J]. Molecular Cancer, 2019, 18(1): 47. DOI:10.1186/s12943-019-1010-6 |
[42] |
WEHR M C, HOLDER M V, GAILITE I, et al. Salt-inducible kinases regulate growth through the Hippo signalling pathway in Drosophila[J]. Nature Cell Biology, 2013, 15(1): 61-71. DOI:10.1038/ncb2658 |
[43] |
IWASA H, HOSSAIN S, HATA Y. Tumor suppressor C-RASSF proteins[J]. Cellular and Molecular Life Sciences, 2018, 75(10): 1773-1787. DOI:10.1007/s00018-018-2756-5 |
[44] |
AZAD T, NOURI K, JANSE VAN RENSBURG H J, et al. A gain-of-functional screen identifies the Hippo pathway as a central mediator of receptor tyrosine kinases during tumorigenesis[J]. Oncogene, 2020, 39(2): 334-355. DOI:10.1038/s41388-019-0988-y |
[45] |
YU F X, ZHAO B, PANUPINTHU N, et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling[J]. Cell, 2012, 150(4): 780-791. DOI:10.1016/j.cell.2012.06.037 |
[46] |
MA Y W, WANG L H, HE F L, et al. LACTB suppresses melanoma progression by attenuating PP1A and YAP interaction[J]. Cancer Letters, 2021, 506: 67-82. DOI:10.1016/j.canlet.2021.02.022 |
[47] |
HUANG S S, CAO Y, GUO H, et al. Up-regulated acylglycerol kinase (AGK) expression associates with gastric cancer progression through the formation of a novel YAP1-AGK-positive loop[J]. Journal of Cellular and Molecular Medicine, 2020, 24(19): 11133-11145. DOI:10.1111/jcmm.15613 |
[48] |
HUANG Z H, SUN D, HU J X, et al. Neogenin promotes BMP2 activation of YAP and Smad1 and enhances astrocytic differentiation in developing mouse neocortex[J]. Journal of Neuroscience, 2016, 36(21): 5833-5849. DOI:10.1523/JNEUROSCI.4487-15.2016 |
[49] |
PULKKINEN H H, KIEMA M, LAPPALAINEN J P, et al. BMP6/TAZ-Hippo signaling modulates angiogenesis and endothelial cell response to VEGF[J]. Angiogenesis, 2021, 24(1): 129-144. DOI:10.1007/s10456-020-09748-4 |
[50] |
KIM J, KWON H, SHIN Y K, et al. MAML1/2 promote YAP/TAZ nuclear localization and tumorigenesis[J]. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117(24): 13529-13540. DOI:10.1073/pnas.1917969117 |
[51] |
VERMA N K, GADI A, MAURIZI G, et al. Myeloid zinc finger 1 and GA binding protein co-operate with Sox2 in regulating the expression of yes-associated protein 1 in cancer cells[J]. Stem Cells, 2017, 35(12): 2340-2350. DOI:10.1002/stem.2705 |
[52] |
MIAO J B, KYOYAMA H, LIU L W, et al. Inhibition of cyclin-dependent kinase 7 down-regulates yes-associated protein expression in mesothelioma cells[J]. Journal of Cellular and Molecular Medicine, 2020, 24(1): 1087-1098. DOI:10.1111/jcmm.14841 |
[53] |
GONZÁLEZ-MARISCAL L, GALLEGO-GUTIÉRREZ H, GONZÁLEZ-GONZÁLEZ L, et al. ZO-2 is a master regulator of gene expression, cell proliferation, cytoarchitecture, and cell size[J]. International Journal of Molecular Sciences, 2019, 20(17): 4128. DOI:10.3390/ijms20174128 |
[54] |
CAI X M, WANG K C, MENG Z P. Mechanoregulation of YAP and TAZ in cellular homeostasis and disease progression[J]. Frontiers in Cell and Developmental Biology, 2021, 9: 673599. DOI:10.3389/fcell.2021.673599 |
[55] |
DENG H, WANG W, YU J Z, et al. Spectrin regulates Hippo signaling by modulating cortical actomyosin activity[J]. eLife, 2015, 4: e06567. DOI:10.7554/eLife.06567 |
[56] |
FLETCHER G C, ELBEDIWY A, KHANAL I, et al. The spectrin cytoskeleton regulates the hippo signalling pathway[J]. The EMBO Journal, 2015, 34(7): 940-954. DOI:10.15252/embj.201489642 |
[57] |
NAWAZ Z, PATIL V, ARORA A, et al. Cbx7 is epigenetically silenced in glioblastoma and inhibits cell migration by targeting YAP/TAZ-dependent transcription[J]. Scientific Reports, 2016, 6(1): 27753. DOI:10.1038/srep27753 |
[58] |
LEE J S, PARK H W, CHO K J, et al. Sestrin2 inhibits YAP activation and negatively regulates corneal epithelial cell proliferation[J]. Experimental & Molecular Medicine, 2020, 52(6): 951-962. |
[59] |
JIAO S, WANG H Z, SHI Z B, et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer[J]. Cancer Cell, 2014, 25(2): 166-180. DOI:10.1016/j.ccr.2014.01.010 |
[60] |
CLARKE L E, COOK A, MATHAVARAJAH S, et al. Haploinsufficient tumor suppressor PRP4K is negatively regulated during epithelial-to-mesenchymal transition[J]. FASEB Journal, 2021, 35(11): e22001. |
[61] |
JIA L L, ZHANG Y P, JI Y W, et al. YAP balances the osteogenic and adipogenic differentiation of hPDLSCs in vitro partly through the Wnt/β-catenin signaling pathway[J]. Biochemical and Biophysical Research Communications, 2019, 518(1): 154-160. DOI:10.1016/j.bbrc.2019.08.024 |
[62] |
ZHOU D W, CONRAD C, XIA F, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene[J]. Cancer Cell, 2009, 16(5): 425-438. DOI:10.1016/j.ccr.2009.09.026 |
[63] |
LEE J H, KIM T S, YANG T H, et al. A crucial role of WW45 in developing epithelial tissues in the mouse[J]. The EMBO Journal, 2008, 27(8): 1231-1242. DOI:10.1038/emboj.2008.63 |
[64] |
NISHIO M, HAMADA K, KAWAHARA K, et al. Cancer susceptibility and embryonic lethality in Mob1a/1b double-mutant mice[J]. The Journal of Clinical Investigation, 2012, 122(12): 4505-4518. DOI:10.1172/JCI63735 |
[65] |
SINGH K, PRUSKI M A, POLIREDDY K, et al. Mst1/2 kinases restrain transformation in a novel transgenic model of Ras driven non-small cell lung cancer[J]. Oncogene, 2020, 39(5): 1152-1164. DOI:10.1038/s41388-019-1031-z |
[66] |
LI W L, DENG Y J, FENG B, et al. Mst1/2 kinases modulate glucose uptake for osteoblast differentiation and bone formation[J]. Journal of Bone and Mineral Research, 2018, 33(6): 1183-1195. DOI:10.1002/jbmr.3413 |
[67] |
DENG Y J, LU J Q, LI W L, et al. Reciprocal inhibition of YAP/TAZ and NF-κB regulates osteoarthritic cartilage degradation[J]. Nature Communications, 2018, 9(1): 4564. DOI:10.1038/s41467-018-07022-2 |
[68] |
MENG C L, TIAN G, XU C H, et al. Hippo kinases MST1 and MST2 control the differentiation of the epididymal initial segment via the MEK-ERK pathway[J]. Cell Death and Differentiation, 2020, 27(10): 2797-2809. DOI:10.1038/s41418-020-0544-x |
[69] |
WANG P, GENG J, GAO J H, et al. Macrophage achieves self-protection against oxidative stress-induced ageing through the Mst-Nrf2 axis[J]. Nature Communications, 2019, 10(1): 755. DOI:10.1038/s41467-019-08680-6 |
[70] |
LEUNG J Y, WILSON H L, VOLTZKE K J, et al. Sav1 loss induces senescence and Stat3 activation coinciding with tubulointerstitial fibrosis[J]. Molecular and Cellular Biology, 2017, 37(12): e00565-16. |
[71] |
KAI T, TSUKAMOTO Y, HIJIYA N, et al. Kidney-specific knockout of Sav1 in the mouse promotes hyperproliferation of renal tubular epithelium through suppression of the Hippo pathway[J]. The Journal of Pathology, 2016, 239(1): 97-108. DOI:10.1002/path.4706 |
[72] |
JEONG S H, KIM H B, KIM M C, et al. Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer[J]. The Journal of Clinical Investigation, 2018, 128(3): 1010-1025. DOI:10.1172/JCI95802 |
[73] |
TAMURA T, KODAMA T, SATO K, et al. Dysregulation of PI3K and hippo signaling pathways synergistically induces chronic pancreatitis via CTGF upregulation[J]. The Journal of Clinical Investigation, 2021, 131(13): 143414. DOI:10.1172/JCI143414 |
[74] |
ZHANG X Y, GUO C, WU X W, et al. Analysis of liver tumor-prone mouse models of the hippo kinase scaffold proteins RASSF1A and SAV1[J]. Cancer Research, 2016, 76(9): 2824-2835. DOI:10.1158/0008-5472.CAN-15-3010 |
[75] |
COTTON J L, LI Q, MA L F, et al. YAP/TAZ and hedgehog coordinate growth and patterning in gastrointestinal mesenchyme[J]. Developmental Cell, 2017, 43(1): 35-47.e4. DOI:10.1016/j.devcel.2017.08.019 |
[76] |
GUILLERMIN O, ANGELIS N, SIDOR C M, et al. Wnt and Src signals converge on YAP-TEAD to drive intestinal regeneration[J]. The EMBO Journal, 2021, 40(13): e105770. |
[77] |
HONG S P, YANG M J, CHO H, et al. Distinct fibroblast subsets regulate lacteal integrity through YAP/TAZ-induced VEGF-C in intestinal villi[J]. Nature Communications, 2020, 11(1): 4102. DOI:10.1038/s41467-020-17886-y |
[78] |
CHEUNG P, XIOL J, DILL M T, et al. Regenerative reprogramming of the intestinal stem cell state via Hippo signaling suppresses metastatic colorectal cancer[J]. Cell Stem Cell, 2020, 27(4): 590-604.e9. DOI:10.1016/j.stem.2020.07.003 |
[79] |
WU L M N, DENG Y Q, WANG J C, et al. Programming of Schwann cells by Lats1/2-TAZ/YAP signaling drives malignant peripheral nerve sheath tumorigenesis[J]. Cancer Cell, 2018, 33(2): 292-308.e7. DOI:10.1016/j.ccell.2018.01.005 |
[80] |
CHEN Z G, LI S, MO J, et al. Schwannoma development is mediated by Hippo pathway dysregulation and modified by RAS/MAPK signaling[J]. JCI Insight, 2020, 5(20): e141514. DOI:10.1172/jci.insight.141514 |
[81] |
NANTIE L B, YOUNG R E, PALTZER W G, et al. Lats1/2 inactivation reveals Hippo function in alveolar type Ⅰ cell differentiation during lung transition to air breathing[J]. Development, 2018, 145(21): dev163105. |
[82] |
PARK J, KIM J S, NAHM J H, et al. WWC1 and NF2 prevent the development of intrahepatic cholangiocarcinoma by regulating YAP/TAZ activity through LATS in mice[J]. Molecules and Cells, 2020, 43(5): 491-499. |
[83] |
XIAO Y, HILL M C, LI L L, et al. Hippo pathway deletion in adult resting cardiac fibroblasts initiates a cell state transition with spontaneous and self-sustaining fibrosis[J]. Genes & Development, 2019, 33(21/22): 1491-1505. |
[84] |
BAE J S, JEON Y, KIM S M, et al. Depletion of MOB1A/B causes intestinal epithelial degeneration by suppressing Wnt activity and activating BMP/TGF-β signaling[J]. Cell Death & Disease, 2018, 9(11): 1083. |
[85] |
OMORI H, NISHIO M, MASUDA M, et al. YAP1 is a potent driver of the onset and progression of oral squamous cell carcinoma[J]. Science Advances, 2020, 6(12): eaay3324. DOI:10.1126/sciadv.aay3324 |
[86] |
OTSUBO K, GOTO H, NISHIO M, et al. MOB1-YAP1/TAZ-NKX2.1 axis controls bronchioalveolar cell differentiation, adhesion and tumour formation[J]. Oncogene, 2017, 36(29): 4201-4211. DOI:10.1038/onc.2017.58 |
[87] |
GOTO H, NISHIO M, TO Y, et al. Loss of Mob1a/b in mice results in chondrodysplasia due to YAP1/TAZ-TEAD-dependent repression of SOX9[J]. Development, 2018, 145(6): dev159244. |
[88] |
XIN M, KIM Y, SUTHERLAND L B, et al. Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size[J]. Science Signaling, 2011, 4(196): ra70. |
[89] |
XIN M, KIM Y, SUTHERLAND L B, et al. Hippo pathway effector Yap promotes cardiac regeneration[J]. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110(34): 13839-13844. DOI:10.1073/pnas.1313192110 |
[90] |
BYUN J, DEL RE D P, ZHAI P Y, et al. Yes-associated protein (YAP) mediates adaptive cardiac hypertrophy in response to pressure overload[J]. The Journal of Biological Chemistry, 2019, 294(10): 3603-3617. DOI:10.1074/jbc.RA118.006123 |
[91] |
ISAGO H, MITANI A, MIKAMI Y, et al. Epithelial expression of YAP and TAZ is sequentially required in lung development[J]. American Journal of Respiratory Cell and Molecular Biology, 2020, 62(2): 256-266. DOI:10.1165/rcmb.2019-0218OC |
[92] |
AI L Q Y, YUAN R D, CHEN X, et al. Retinal blood vessel-origin yes-associated protein (YAP) governs astrocytic maturation via leukaemia inhibitory factor (LIF)[J]. Cell Proliferation, 2020, 53(2): e12757. |
[93] |
DAI Y J, HAO P, SUN Z M, et al. Liver knockout YAP gene improved insulin resistance-induced hepatic fibrosis[J]. Journal of Endocrinology, 2021, 249(2): 149-161. DOI:10.1530/JOE-20-0561 |
[94] |
LEE Y A, NOON L A, AKAT K M, et al. Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap[J]. Nature Communications, 2018, 9(1): 4962. DOI:10.1038/s41467-018-07338-z |
[95] |
ZHAO K, SHEN C Y, LU Y S, et al. Muscle Yap is a regulator of neuromuscular junction formation and regeneration[J]. Journal of Neuroscience, 2017, 37(13): 3465-3477. DOI:10.1523/JNEUROSCI.2934-16.2017 |
[96] |
HUANG Z H, HU J X, PAN J X, et al. YAP stabilizes SMAD1 and promotes BMP2-induced neocortical astrocytic differentiation[J]. Development, 2016, 143(13): 2398-2409. DOI:10.1242/dev.130658 |
[97] |
LACANNA R, LICCARDO D, ZHANG P, et al. Yap/Taz regulate alveolar regeneration and resolution of lung inflammation[J]. The Journal of Clinical Investigation, 2019, 129(5): 2107-2122. DOI:10.1172/JCI125014 |
[98] |
VANYAI H K, PRIN F, GUILLERMIN O, et al. Control of skeletal morphogenesis by the Hippo-YAP/TAZ pathway[J]. Development, 2020, 147(21): dev187187. |
[99] |
MIA M M, CIBI D M, BINTE ABDUL GHANI S A, et al.Loss of Yap/Taz in cardiac fibroblasts attenuates adverse remodeling and improves cardiac function[J/OL]. Cardiovascular Research, 2021: cvab205.(2021-06-16)[2021-06-16]. https://pubmed.ncbi.nlm.nih.gov/34132780.DOI: 10.1093/cvr/cvab205.
|
[100] |
MIA M M, CIBI D M, ABDUL GHANI S A B, et al. YAP/TAZ deficiency reprograms macrophage phenotype and improves infarct healing and cardiac function after myocardial infarction[J]. PLoS Biology, 2020, 18(12): e3000941. DOI:10.1371/journal.pbio.3000941 |
[101] |
LIU W A, CHEN S, LI Z Z, et al. PARD3 dysfunction in conjunction with dynamic HIPPO signaling drives cortical enlargement with massive heterotopia[J]. Genes & Development, 2018, 32(11/12): 763-780. |
[102] |
OKUYAMA M, JIANG W H, YANG L H, et al. Mst1/2 kinases inhibitor, XMU-MP-1, attenuates angiotensin Ⅱ-induced ascending aortic expansion in hypercholesterolemic mice[J]. Circulation Reports, 2021, 3(5): 259-266. DOI:10.1253/circrep.CR-20-0104 |
[103] |
BASU D, LETTAN R, DAMODARAN K, et al. Identification, mechanism of action, and antitumor activity of a small molecule inhibitor of Hippo, TGF-β, and Wnt signaling pathways[J]. Molecular Cancer Therapeutics, 2014, 13(6): 1457-1467. DOI:10.1158/1535-7163.MCT-13-0918 |
[104] |
TANG Y, FANG G M, GUO F H, et al. Selective inhibition of STRN3-containing PP2A phosphatase restores Hippo tumor-suppressor activity in gastric cancer[J]. Cancer Cell, 2020, 38(1): 115-128.e9. DOI:10.1016/j.ccell.2020.05.019 |
[105] |
SONG J, GAO Q L, WU B W, et al. Discovery of tertiary amide derivatives incorporating benzothiazole moiety as anti-gastric cancer agents in vitro via inhibiting tubulin polymerization and activating the Hippo signaling pathway[J]. European Journal of Medicinal Chemistry, 2020, 203: 112618. DOI:10.1016/j.ejmech.2020.112618 |
[106] |
WANG Q, LU P, WANG T, et al. Sitagliptin affects gastric cancer cells proliferation by suppressing melanoma-associated antigen-A3 expression through yes-associated protein inactivation[J]. Cancer Medicine, 2020, 9(11): 3816-3828. DOI:10.1002/cam4.3024 |
[107] |
ZHAO S, XU K, JIANG R, et al. Evodiamine inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells via the Hippo-Yes-associated protein signaling pathway[J]. Life Sciences, 2020, 251: 117424. DOI:10.1016/j.lfs.2020.117424 |
[108] |
YE C M, WANG W Q, XIA G J, et al. A novel curcumin derivative CL-6 exerts antitumor effect in human gastric cancer cells by inducing apoptosis through Hippo-YAP signaling pathway[J]. OncoTargets and Therapy, 2019, 12: 2259-2269. DOI:10.2147/OTT.S196914 |
[109] |
DENT P, BOOTH L, ROBERTS J L, et al. Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells[J]. Oncogene, 2019, 38(30): 5890-5904. DOI:10.1038/s41388-019-0849-8 |
[110] |
DONG W H, DONG Q, DING H R. Ophiopogonin B induces reactive oxygen species dependent apoptosis through the Hippo pathway in nasopharyngeal carcinoma[J]. Molecular Medicine Reports, 2021, 24(1): 534. DOI:10.3892/mmr.2021.12173 |
[111] |
CHAI Y T, XIANG K, WU Y Z, et al. Cucurbitacin B inhibits the Hippo-YAP signaling pathway and exerts anticancer activity in colorectal cancer cells[J]. Medical Science Monitor, 2018, 24: 9251-9258. DOI:10.12659/MSM.911594 |
[112] |
LIU J, LI J, CHEN H, et al. Metformin suppresses proliferation and invasion of drug-resistant breast cancer cells by activation of the Hippo pathway[J]. Journal of Cellular and Molecular Medicine, 2020, 24(10): 5786-5796. DOI:10.1111/jcmm.15241 |
[113] |
WANG H N, WANG R, HUANG D, et al. Homoharringtonine exerts anti-tumor effects in hepatocellular carcinoma through activation of the Hippo pathway[J]. Frontiers in Pharmacology, 2021, 12: 592071. DOI:10.3389/fphar.2021.592071 |
[114] |
TAN S J, ZHAO Z, QIAO Y N, et al. Activation of the tumor suppressive Hippo pathway by triptonide as a new strategy to potently inhibit aggressive melanoma cell metastasis[J]. Biochemical Pharmacology, 2021, 185: 114423. DOI:10.1016/j.bcp.2021.114423 |
[115] |
TAO L C, CHEN X, ZHENG Y F, et al. Chinese propolis suppressed pancreatic cancer Panc-1 cells proliferation and migration via Hippo-YAP pathway[J]. Molecules, 2021, 26(9): 2803. DOI:10.3390/molecules26092803 |
[116] |
WANG W S, HUANG Q J, CHEN Y, et al. The novel FAT4 activator jujuboside A suppresses NSCLC tumorigenesis by activating HIPPO signaling and inhibiting YAP nuclear translocation[J]. Pharmacological Research, 2021, 170: 105723. DOI:10.1016/j.phrs.2021.105723 |
[117] |
JIAO T Y, YAO X P, ZHAO Y Y, et al. Dexamethasone-induced liver enlargement is related to PXR/YAP activation and lipid accumulation but not hepatocyte proliferation[J]. Drug Metabolism and Disposition, 2020, 48(9): 830-839. DOI:10.1124/dmd.120.000061 |
[118] |
WANG C, ZHU X Y, FENG W W, et al. Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm[J]. American Journal of Cancer Research, 2016, 6(1): 27-37. |
[119] |
LI Y J, LU J, CHEN Q, et al. Artemisinin suppresses hepatocellular carcinoma cell growth, migration and invasion by targeting cellular bioenergetics and Hippo-YAP signaling[J]. Archives of Toxicology, 2019, 93(11): 3367-3383. DOI:10.1007/s00204-019-02579-3 |
[120] |
FU W W, ZHAO P, LI H, et al. Bazedoxifene enhances paclitaxel efficacy to suppress glioblastoma via altering Hippo/YAP pathway[J]. Journal of Cancer, 2020, 11(3): 657-667. DOI:10.7150/jca.38350 |
[121] |
JI X Y, SONG L H, SHENG L, et al. Cyclopeptide RA-V inhibits organ enlargement and tumorigenesis induced by YAP activation[J]. Cancers, 2018, 10(11): 449. DOI:10.3390/cancers10110449 |
[122] |
WANG Z Y, WU Y P, WANG H F, et al. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility[J]. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111(1): E89-E98. |
[123] |
LIU D D, LYU H, LIU Q, et al. Atheroprotective effects of methotrexate via the inhibition of YAP/TAZ under disturbed flow[J]. Journal of Translational Medicine, 2019, 17(1): 378. DOI:10.1186/s12967-019-02135-8 |
[124] |
CHENG Y, CHEN T Y, CHEN J J. Erzhu Jiedu decoction ameliorates liver precancerous lesions in a rat model of liver cancer[J]. Journal of Cancer, 2020, 11(24): 7302-7311. DOI:10.7150/jca.49554 |
[125] |
SONG S M, XIE M, SCOTT A W, et al. A novel YAP1 inhibitor targets CSC-enriched radiation-resistant cells and exerts strong antitumor activity in esophageal adenocarcinoma[J]. Molecular Cancer Therapeutics, 2018, 17(2): 443-454. DOI:10.1158/1535-7163.MCT-17-0560 |
[126] |
CHAO Y C, LEE K Y, WU S M, et al. Melatonin downregulates PD-L1 expression and modulates tumor immunity in KRAS-mutant non-small cell lung cancer[J]. International Journal of Molecular Sciences, 2021, 22(11): 5649. DOI:10.3390/ijms22115649 |
[127] |
SAUNDERS J T, HOLMES B, BENAVIDES-SERRATO A, et al. Targeting the YAP-TEAD interaction interface for therapeutic intervention in glioblastoma[J]. Journal of Neuro-Oncology, 2021, 152(2): 217-231. DOI:10.1007/s11060-021-03699-6 |
[128] |
LORTHONGPANICH C, CHAROENWONGPAIBOON T, SUPAKUN P, et al. Fisetin inhibits osteogenic differentiation of mesenchymal stem cells via the inhibition of YAP[J]. Antioxidants, 2021, 10(6): 879. DOI:10.3390/antiox10060879 |
[129] |
MÉLIN L, ABDULLAYEV S, FNAICHE A, et al. Development of LM98, a small-molecule TEAD inhibitor derived from flufenamic acid[J]. ChemMedChem, 2021, 16(19): 2982-3002. DOI:10.1002/cmdc.202100432 |
[130] |
SMITH S A, SESSIONS R B, SHOEMARK D K, et al. Antiproliferative and antimigratory effects of a novel YAP-TEAD interaction inhibitor identified using in silico molecular docking[J]. Journal of Medicinal Chemistry, 2019, 62(3): 1291-1305. DOI:10.1021/acs.jmedchem.8b01402 |
[131] |
KIM S H, JIN H, MENG R Y, et al. Activating Hippo pathway via Rassf1 by ursolic acid suppresses the tumorigenesis of gastric cancer[J]. International Journal of Molecular Sciences, 2019, 20(19): 4709. DOI:10.3390/ijms20194709 |
[132] |
XUE M L, LIANG H, JI X Q, et al. Effects of fucoidan on gut flora and tumor prevention in 1, 2-dimethylhydrazine-induced colorectal carcinogenesis[J]. The Journal of Nutritional Biochemistry, 2020, 82: 108396. DOI:10.1016/j.jnutbio.2020.108396 |
[133] |
ZHENG Y Z, YANG X P, TAN J, et al. Curcumin suppresses the stemness of non-small cell lung cancer cells via promoting the nuclear-cytoplasm translocation of TAZ[J]. Environmental Toxicology, 2021, 36(6): 1135-1142. DOI:10.1002/tox.23112 |
[134] |
GAO Y, SHI Q, XU S, et al. Curcumin promotes KLF5 proteasome degradation through downregulating YAP/TAZ in bladder cancer cells[J]. International Journal of Molecular Sciences, 2014, 15(9): 15173-15187. DOI:10.3390/ijms150915173 |
[135] |
WANG Z L, XING W, SONG Y L, et al. Folic acid has a protective effect on retinal vascular endothelial cells against high glucose[J]. Molecules, 2018, 23(9): 2326. DOI:10.3390/molecules23092326 |
[136] |
HONG L, ZHA Y J, WANG C, et al. Folic acid alleviates high glucose and fat-induced pyroptosis via inhibition of the Hippo signal pathway on H9C2 cells[J]. Frontiers in Molecular Biosciences, 2021, 8: 698698. DOI:10.3389/fmolb.2021.698698 |
[137] |
TRUJILLO-GONZALEZ I, FRIDAY W B, MUNSON C A, et al. Low availability of choline in utero disrupts development and function of the retina[J]. FASEB Journal, 2019, 33(8): 9194-9209. DOI:10.1096/fj.201900444R |
[138] |
WANG Z H, LI L, GU W W, et al. Resveratrol reverses osteogenic decline of bone marrow mesenchymal stem cells via upregulation of YAP expression in inflammatory environment[J]. Stem Cells and Development, 2021, 30(24): 1202-1214. DOI:10.1089/scd.2021.0195 |
[139] |
KIM Y N, CHOE S R, CHO K H, et al. Resveratrol suppresses breast cancer cell invasion by inactivating a RhoA/YAP signaling axis[J]. Experimental & Molecular Medicine, 2017, 49(2): e296. |
[140] |
XU G R, CHEN J Z, WANG G R, et al. Resveratrol inhibits the tumorigenesis of follicular thyroid cancer via ST6GAL2-regulated activation of the Hippo signaling pathway[J]. Molecular Therapy Oncolytics, 2020, 16: 124-133. DOI:10.1016/j.omto.2019.12.010 |
[141] |
JIANG Z D, CHEN X, CHEN K, et al. YAP inhibition by resveratrol via activation of AMPK enhances the sensitivity of pancreatic cancer cells to gemcitabine[J]. Nutrients, 2016, 8(10): 546. DOI:10.3390/nu8100546 |
[142] |
LI C X, ZHANG R R, ZHAN Y T, et al. Resveratrol inhibits hepatic stellate cell activation via the Hippo pathway[J]. Mediators of Inflammation, 2021, 2021: 3399357. |